CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 18 enrolled
Drug / intervention
CT scandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01673802
NCT01673802Early Ph 1Completed
CompareCT.gov

The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma

University of Alabama at Birmingham·interventional·Posted Aug 28, 2012·Updated Jun 1, 2017

In Brief

A Early Phase 1 clinical trial evaluating CT scan for Cholangiocarcinoma. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma. This pilot project aims to address a long-term pitfall in the imaging of cholangiocarcinomas, by providing higher resolution delineation of these often infiltrative tumors on single-source, Dual-Energy Spectral Multi Detector CT (MDCT), capitalizing on improved spatial resolution achievable with MDCT compared to MRI and at the same time producing a non-invasive CT cholangiogram to aid in accurate diagnosis and treatment planning of cholangiocarcinoma, particularly, the hilar variety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesUnited States
CollaboratorsSociety of Abdominal Radiology

Timeline

Early Ph 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 28, 2012
Enrollment StartAug 1, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.8 years ago

Interventions

CT scandrug

Gadoxetate (Eovist) enhanced dual energy CT